Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
8-K
Other material
confidence 72%
filed 2026-06-10
Item 8.01
The disclosure announces the expiration and final results of debt exchange offers and consent solicitations by Qwest/Lumen to exchange approximately $2 billion in outstanding notes (2056 and 2057 notes) for new notes with shorter maturities (2051 and 2052). While this involves debt restructuring, it does not fit cleanly into the "ma_activity" category (which typically covers acquisitions, dispositions, mergers, or changes of control) nor does it constitute a covenant breach, restatement, or other more specific event type. The exchange offer completion is material to investors as it affects the company's debt structure and maturity profile, but the specific event—completion of a debt exchange offer—lacks a dedicated taxonomy category.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-10
Item 5.07
This is a classic Item 5.07 disclosure of shareholder vote results from QNB Corp.'s June 9, 2026 Annual Meeting of Shareholders. The filing reports voting outcomes on three proposals: election of Class II directors (Bergman, Bimes, Brown, and Stauffer), approval of the 2026 Employee Stock Purchase Plan, and ratification of Baker Tilly US, LLP as independent auditor. All proposals passed with substantial majorities, making this a material governance event that investors rely on to confirm board composition and audit oversight.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-06-10
Item 8.01
National Fuel Gas Company disclosed the offering and sale of $1.5 billion in aggregate principal amount of senior notes across three tranches (2029, 2031, and 2036 maturities) with rates ranging from 4.75% to 5.50%. While this is a material debt issuance that would affect a reasonable investor's assessment of the company's capital structure and financial obligations, it does not fit cleanly into the "dilutive_issuance" category (which focuses on equity securities) or "ma_activity" (which addresses acquisitions, dispositions, or changes of control). The disclosure is material but represents a debt financing event that falls outside the more specific taxonomy categories.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-10
Item 5.07
This is a classic Item 5.07 disclosure reporting the results of the 2026 Annual Meeting of Stockholders held on June 9, 2026. The filing presents voting results for two proposals: election of Class II directors (H. Edward Fleming, Jr., M.D. and Liam Ratcliffe, M.B.Ch.B., Ph.D., M.B.A.) and ratification of PricewaterhouseCoopers LLP as independent auditor. Both proposals passed with strong majorities, making this a routine but material shareholder governance event.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-06-10
Item 5.07
This Item 5.07 disclosure reports the results of Solid Biosciences' Annual Meeting of Stockholders held on June 10, 2026, covering five matters: election of Class II directors (Clare Kahn, Adam Stone, Lynne Sullivan), ratification of Class I director Ilan Ganot, ratification of PricewaterhouseCoopers LLP as independent auditor, approval of a Share Increase Amendment (doubling authorized common shares from 240M to 480M), and advisory approval of named executive officer compensation. The filing includes detailed vote tallies for each matter, confirming the core purpose of Item 5.07 shareholder vote result disclosure.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-06-10
Item 8.01
The Board approved a 2026 Common Share Repurchase Program authorizing up to 500,000 shares with a maximum aggregate purchase price of $15,000,000. While share repurchase programs are routine capital allocation decisions, this authorization is material to investors as it signals management's confidence in valuation, affects share count and EPS calculations, and represents a significant deployment of capital. The disclosure does not fit neatly into the more specific event categories (not an earnings release, executive change, M&A, impairment, or litigation), making "other_material" the appropriate classification.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-10
Item 5.07
This is a clear disclosure of shareholder voting results from enGene Therapeutics' 2026 Annual General Meeting held on June 9, 2026. The filing reports final voting tallies for Proposal 1 (Election of Directors) and Proposal 2 (Appointment and Remuneration of Auditor), with detailed vote counts for each director nominee and the auditor appointment. This is a quintessential Item 5.07 disclosure required by SEC rules and is material to investors as it confirms board composition and auditor selection.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-06-10
Item 8.01
IDEAYA completed a public offering of 7,222,225 shares of common stock and pre-funded warrants to purchase 5,555,576 additional shares, raising approximately $323.6 million in net proceeds. This is a material dilutive equity issuance disclosed under Item 8.01, representing a substantial increase in shares outstanding and capital raise that would affect a reasonable investor's assessment of ownership dilution and the company's financial position.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-10
Item 5.07
This is a classic Item 5.07 disclosure reporting the results of Prelude Therapeutics' 2026 Annual Meeting of Stockholders held on June 9, 2026. The filing presents voting results for four proposals: election of three Class III directors (Krishna Vaddi, Paul Scherer, and Katina Dorton), ratification of Ernst & Young LLP as independent auditor, advisory vote on named executive officer compensation, and advisory vote on the frequency of compensation votes. All proposals were approved by stockholders, with detailed vote tallies provided for each nominee and proposal.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-10
Item 5.07
This is a clear disclosure of shareholder vote results from Rapport Therapeutics' 2026 Annual Meeting of Stockholders held on June 10, 2026. The filing reports voting outcomes for two proposals: (i) election of three Class II directors (James Healy, Robert J. Perez, and Raymond Sanchez) and (ii) ratification of PwC as the independent auditor. The detailed vote tallies (For/Withheld/Broker Non-Votes for directors; For/Against/Abstain for auditor ratification) are the core content of Item 5.07, making this a textbook shareholder_vote_results event that is material to investors assessing board composition and audit oversight.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-06-10
Item 2.02
Oracle issued a press release on June 10, 2026 announcing financial results for its fiscal fourth quarter ended May 31, 2026, disclosing quarterly financial performance and results of operations.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-10
Item 5.07
This is a classic Item 5.07 disclosure reporting the results of Amplitude's 2026 annual meeting of stockholders held on June 9, 2026. The filing presents voting results for three proposals: election of Class II directors (Pat Grady, Curtis Liu, Catherine Wong), ratification of KPMG LLP as independent auditor, and advisory approval of named executive officer compensation. The detailed vote tallies (votes for, against, abstentions, and broker non-votes) are the core content of the disclosure.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-10
Item 5.07
Syndax Pharmaceuticals held its Annual Meeting of Stockholders on June 10, 2026, with shareholders voting on five proposals: election of directors (Legault and Metzger), advisory vote on executive compensation, ratification of auditors, and approval of the 2026 Equity Incentive Plan and 2026 Employee Stock Purchase Plan. All proposals passed.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-06-10
Item 5.02
Elizabeth S. Perkins, the Company's Senior Vice President and Chief Financial Officer, was appointed to the additional role of principal accounting officer on June 10, 2026, succeeding Rachel Labrecque who passed away on June 9, 2026. While the disclosure involves a departure (Labrecque's death), the principal disclosed action is Perkins' appointment to a key accounting role, making exec_appointment the most salient classification. The appointment of a principal accounting officer is material to investors as it affects financial reporting oversight and governance.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-10
Item 5.07
This is a clear disclosure of shareholder vote results from MarketAxess Holdings' 2026 Annual Meeting of Stockholders held on June 10, 2026, filed under Item 5.07. The filing reports voting outcomes for four proposals: election of 12 directors, ratification of PricewaterhouseCoopers LLP as auditor, advisory vote on named executive officer compensation ("say-on-pay"), and a stockholder proposal regarding special meeting rights. All proposals passed with substantial majorities. This is material as it reflects shareholder approval of governance and compensation matters.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-10
Item 5.07
This Item 5.07 filing discloses the final voting results from Aimco's 2026 Annual Meeting of Stockholders held on June 10, 2026, covering three proposals: election of nine directors, ratification of Grant Thornton LLP as independent auditor, and advisory approval of executive compensation. The detailed tabulation of votes for and against each proposal is the core disclosure required under Item 5.07.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-10
Item 5.07
This is a classic Item 5.07 disclosure of shareholder vote results from Maze Therapeutics' 2026 annual meeting held on June 8, 2026. The filing reports voting outcomes for two proposals: election of directors Jason Coloma and Neil Kumar (both elected), and ratification of Ernst & Young LLP as independent auditor (ratified with overwhelming support). The detailed vote tallies and quorum confirmation are hallmarks of shareholder_vote_results disclosures.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-06-10
Item 5.02
The filing discloses the appointment of Ma. Fatima D. Francisco to the Board of Directors as a Class I director, effective June 15, 2026. While the disclosure also includes compensatory arrangements (annual retainer of $50,000 and an option grant of 85,937 shares), the principal action is the appointment itself. The appointment of a new director is material to investors as it affects board composition and governance.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-10
Item 5.07
This is a clear disclosure of shareholder vote results from Exzeo Group's Annual Meeting of Shareholders held on June 9, 2026. The filing reports voting outcomes for two proposals: (1) election of two Class A directors (Paresh Patel and Irene Hurst) and (2) ratification of Forvis Mazars, LLP as independent auditor. The specific vote tallies (For, Against, Withheld, Abstained) are provided for each matter, which is the hallmark of Item 5.07 shareholder vote results disclosure.
View raw filing on EDGAR →
8-K
Exec departure
confidence 85%
filed 2026-06-10
Item 5.02
Dr. Anna Eramo, Chief Medical Officer, resigned effective June 15, 2026, and will transition to an advisor role. While the filing emphasizes that her departure is not expected to materially impact clinical development activities, the resignation of a CMO at a clinical-stage pharmaceutical company is a material executive departure that investors would consider significant. The separation agreement with severance and equity acceleration further confirms this is a formal executive departure event.
View raw filing on EDGAR →
8-K
Other material
confidence 70%
filed 2026-06-10
Item 1.01
Dell Technologies entered into a $6 billion senior unsecured revolving credit facility on June 10, 2026, replacing an existing credit agreement. This refinancing arrangement materially affects the company's liquidity and capital structure, though it does not constitute an M&A transaction or change of control.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-06-10
Item 5.07
Stockholders approved six proposals at the Annual Meeting on June 10, 2026, including election of directors, ratification of auditors, approval of a Series B convertible preferred stock issuance that triggers a change of control under Nasdaq rules, authorization of additional common shares, and approval of equity compensation plans.
View raw filing on EDGAR →
8-K
Other material
confidence 55%
filed 2026-06-10
Item 2.03
Northern States Power Company-Wisconsin entered into a Bond Purchase Agreement for $250 million in First Mortgage Bonds due 2041, representing a material debt issuance that affects the company's capital structure and financial obligations.
View raw filing on EDGAR →
8-K
Other material
confidence 45%
filed 2026-06-10
Item 1.01
The company entered into a material definitive agreement disclosed under Item 1.01, though the specific nature of the agreement (whether M&A activity, significant contract, or other transaction) cannot be determined without the full filing text.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-10
Item 8.01
Fifth Third Bancorp completed a material debt restructuring involving exchange offers and consent solicitations on June 10, 2026, exchanging approximately $1.27 billion in Comerica-issued notes (assumed by FTFC) for new Fifth Third Bancorp notes while eliminating significant covenants and events of default from the original indentures. This is a material capital structure event affecting the company's debt obligations and financial flexibility, but does not fit neatly into the more specific categories (not an M&A activity, impairment, or covenant breach—rather a proactive refinancing and covenant elimination). The elimination of restrictive covenants and events of default is particularly significant to investors assessing financial risk.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-10
Item 5.07
This is a classic Item 5.07 disclosure reporting the results of Intellia's Annual Meeting held on June 9, 2026. The filing presents voting results for three proposals: election of three class I directors (Muna Bhanji, Brian Goff, and Jesse Goodman), ratification of Deloitte & Touche LLP as independent auditor, and advisory approval of named executive officer compensation. All three proposals passed with substantial majorities, making this a routine but material shareholder governance disclosure.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-10
Item 5.07
This is a clear disclosure of shareholder vote results from the Annual Meeting of Stockholders held on June 10, 2026. The filing reports voting outcomes for two proposals: (i) election of three Class I directors (Robert Gries, Andrew Wright, and Beth W. Bruce) and (ii) ratification of Forvis Mazars, LLP as independent auditor. The tabulated vote counts for each proposal are provided, which is the hallmark of Item 5.07 shareholder_vote_results disclosures.
View raw filing on EDGAR →
8-K
M&A activity
confidence 94%
filed 2026-06-10
Item 2.01
WhiteHawk Minerals Corp. completed a material internalization transaction in which WhiteHawk OpCo acquired all outstanding equity interests in ManagementCo from the Management Contributor for 3,750,000 common units and Class B shares valued at $97.5 million (75% of a $130 million Internalization Price), with an additional earnout of up to $32.5 million contingent on EBITDA targets. This acquisition transforms the Company from externally managed to internally managed and is accompanied by entry into material definitive agreements including a Contribution Agreement, Amended and Restated Limited Partnership Agreement, and Registration Rights Agreement.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-06-10
Item 3.02
WhiteHawk Minerals issued 3,750,000 shares of Class B Common Stock to the Management Contributor in connection with the internalization transaction, relying on Section 4(a)(2) exemption from registration. This unregistered private placement of equity securities materially dilutes existing shareholders and affects the company's ownership structure and capitalization.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-10
Item 8.01
WhiteHawk Minerals Corp. completed its initial public offering on June 10, 2026, raising approximately $200.2 million in gross proceeds from the sale of 7.7 million shares at $26.00 per share, with listing on the NYSE under ticker 'WHK.' This transformative capital-raising event materially affects the company's capitalization and public market status.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-06-10
Item 5.02
WhiteHawk Minerals appointed four key officers effective upon closing of the offering: Daniel Herz as CEO and President, Jeffrey Slotterback as CFO/Treasurer/Secretary, Stephen Pilatzke as Chief Accounting Officer, and Michael Downs as COO. These material C-suite appointments reflect the company's transition to internal management in connection with its public offering.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-06-10
Item 3.03
WhiteHawk Minerals redeemed all outstanding Series D Preferred Stock for approximately $39.9 million on June 10, 2026. This significant capital event materially affects the rights and economic interests of preferred shareholders and represents a substantial use of capital in connection with the company's public offering.
View raw filing on EDGAR →
8-K
Other material
confidence 45%
filed 2026-06-10
Item 2.03
WhiteHawk Minerals created direct financial obligations through an amendment to a revolving credit facility and a change in issuer under a note purchase agreement in connection with its internalization and public offering. The specific nature and materiality of these obligations depend on whether they involve debt covenant modifications, equity dilution, or other triggering events.
View raw filing on EDGAR →
8-K
Other material
confidence 45%
filed 2026-06-10
Item 5.03
WhiteHawk Minerals amended its Certificate of Incorporation and Bylaws effective June 10, 2026 in connection with its public offering. The disclosure provides limited substantive detail about the specific provisions altered, though the amendments are material to the company's governance structure in connection with going public.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-10
Item 5.07
This is a clear disclosure of shareholder vote results from the 2026 annual meeting held on June 9, 2026, reporting the election of James Gertie as a Class I director with 30,503,999 votes for and 63,545 votes withheld. The filing directly corresponds to Item 5.07 requirements and constitutes a material corporate governance event affecting the composition of the board of directors.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-06-10
Item 1.01
American Eagle entered into Amendment No. 2 to its $700 million ABL Credit Agreement, extending the maturity date from June 2027 to June 2031 and restructuring interest rate terms. This material amendment to a significant credit facility affects the company's debt structure and financial flexibility.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-06-10
Item 7.01
BancFirst Corporation entered into an agreement to acquire Spirit BankCorp, Inc. and SpiritBank, a community bank with approximately $939.6 million in total assets. This is a material acquisition that would significantly affect the registrant's financial position and operations. Although disclosed under Item 7.01 (Regulation FD Disclosure) rather than the typical Item 1.01, the substance is clearly a material M&A transaction requiring classification as ma_activity.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-06-10
Item 1.01
Syndax issued $250 million of convertible senior notes in a private placement on June 10, 2026, with net proceeds of approximately $243 million, creating potential equity dilution of up to 13,631,400 shares upon conversion. The offering was conducted under Section 4(a)(2) of the Securities Act as an unregistered private placement to certain investors.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-10
Item 5.07
Tectonic Therapeutic held its 2026 Annual Meeting of Shareholders on June 8, 2026, with voting results disclosed on three proposals: election of Class II directors Timothy A. Springer and Stefan Vitorovic, ratification of Deloitte & Touche LLP as independent auditor, and advisory approval of executive compensation. All three proposals passed with substantial majorities.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-06-10
Item 8.01
The company announced completion of enrollment in the Phase 2 TX45 APEX clinical trial for a therapeutic candidate targeting pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF). This represents a significant clinical development milestone for the company's pipeline.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-06-10
Item 1.01
Tango Therapeutics entered into an underwriting agreement on June 9, 2026 to conduct an underwritten public offering of 18.2 million shares of common stock and pre-funded warrants to purchase 1.8 million additional shares, with a 30-day overallotment option for 3 million more shares. The offering is expected to raise approximately $566.5 million in net proceeds. This is a material dilutive equity issuance that increases the share count and dilutes existing shareholders, disclosed under Item 1.01 as a material definitive agreement.
View raw filing on EDGAR →
8-K
M&A activity
confidence 72%
filed 2026-06-10
Item 1.01
PureCycle Technologies executed an Eleventh Amendment to its Credit Agreement on June 10, 2026, materially modifying its $200 million revolving credit facility to permit upcoming equity offerings and remove certain secured obligations, restructuring the Company's capital and financing arrangements.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-06-10
Item 8.01
PureCycle Technologies announced its intention to conduct concurrent underwritten public offerings of $250 million in convertible senior notes and $145 million in common stock, representing a material dilutive equity issuance to raise capital.
View raw filing on EDGAR →
8-K
M&A activity
confidence 92%
filed 2026-06-10
Item 7.01
The filing discloses a "previously announced proposed business combination" between Crown PropTech Acquisitions (SPAC) and Mkango Rare Earths Limited, with contemplated private capital raises through equity and debt securities. The disclosure describes ongoing financing activities, investor meetings, and a filed Form F-4 registration statement in furtherance of the business combination, which constitutes material M&A activity under Item 7.01 (Regulation FD Disclosure).
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-06-10
Item 7.01
Rafael Holdings announced completion of the final 96-week study visit in its pivotal Phase 3 TransportNPC™ study for Trappsol® Cyclo™ in Niemann-Pick Disease Type C, with topline data expected in H2 2026. This represents a material clinical milestone for the company's lead therapeutic candidate.
View raw filing on EDGAR →
8-K
M&A activity
confidence 85%
filed 2026-06-10
The filing discloses entry into two non-binding letters of intent: (1) a proposed $5.0 million convertible preferred stock investment from an investor, and (2) a proposed sale of a portion of the operating business for approximately $6.0 million in cash plus assumption of up to $3.0 million in liabilities. These constitute material acquisition and disposition activity under Items 1.01/1.02 that would affect a reasonable investor's assessment of the company's strategic direction and capital structure, despite the non-binding nature of the LOIs.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-06-10
Item 3.02
La Rosa Holdings Corp. issued Series D Preferred Stock to an investor under Rule 506(b) of Regulation D, a private placement exemption for unregistered equity securities. This dilutive issuance materially affects existing shareholders' ownership percentages and signals capital-raising activity.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-10
Item 8.01
This disclosure announces the Company's intent to enter into Non-Redemption Agreements with unaffiliated shareholders in connection with an extraordinary general meeting to approve an extension of time to complete an initial business combination. The agreements would incentivize shareholders not to redeem their Class A shares by offering Class B shares from the Sponsor at a negotiated ratio. While this involves shareholder voting mechanics and potential dilutive equity issuances, the core event is the announcement of a material transaction structure (non-redemption agreements with equity consideration) that affects the capital structure and shareholder base, which does not fit cleanly into the more specific categories but is clearly material to investors assessing the Company's path to completing a business combination.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-10
Item 8.01
Mountain Lake Acquisition Corp. announced a postponement of its extraordinary general meeting from an unspecified earlier date to June 16, 2026, to allow additional time to complete its business combination with Avalanche Treasury Corporation. While the postponement itself is administrative, the underlying business combination approval and the extension of the deadline to consummate the transaction (from June 16 to September 16, 2026) are material to shareholders' assessment of the SPAC's ability to close its transaction. This does not fit neatly into ma_activity (which typically covers entry, completion, or termination of M&A) since the business combination was already approved on June 4, 2026, and this disclosure concerns only a procedural postponement and timeline extension rather than a new M&A event.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-10
Item 8.01
This disclosure reports the consummation of Keystone Acquisition Corp.'s IPO on June 4, 2026, generating $287.5 million in gross proceeds from 28.75 million units, plus a concurrent private placement of 8.47 million warrants for $8.47 million. While the IPO itself is a material capital-raising event, the filing is structured as Item 8.01 (Other Events) rather than Item 2.01 (Completion of Acquisition or Disposition) or a dedicated IPO item, and the disclosure focuses on confirming previously reported facts rather than announcing new material developments. The event is material to investors but does not fit cleanly into the earnings_release, ma_activity, or dilutive_issuance categories as typically understood in the taxonomy.
View raw filing on EDGAR →